AbGenomics International Status
The company raised $16 million of venture funding from undisclosed investors on October 3, 2014.
Developer of antibody therapeutics designed for the treatment of cancer and immune-related inflammatory diseases. The company's antibody therapeutics focus on the discovery and development of novel therapeutics for unmet medical needs in the field of antibody-drug conjugates (ADC) therapy as well as creates a linker-payload that can be utilized for different targeted tumor indications, providing patients with long term drug-free remission of other immune-mediated diseases.
Year Founded
2000
Employees
11
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
AbGenomics International News and Updates
Incredible Growth of Pancreatic And Bile Duct Cancer Drug Market ...
openPR | March 9, 2023
SEA-CD40/Chemo Combo Yields Anti-Tumor Efficacy in PDAC
Cancer Network | January 21, 2023
CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in ...
OncLive | January 20, 2023
Adjuvant nab-Paclitaxel + Gemcitabine in Resected ...
ASCO Journals | December 15, 2022
Organ Preservation in Patients With Rectal Adenocarcinoma ...
ASCO Journals | April 28, 2022
Objective disease activity assessment and therapeutic drug ...
BMC Gastroenterology | February 19, 2022
AbGenomics International's Verticals
AbGenomics International Primary Industry Sector / Group / Code
AbGenomics International's Trends
AbGenomics International Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Headquarters
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ CountryUnited States
AbGenomics International's Keywords
mood_badFeed is empty.
Add a review